SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-019505
Filing Date
2023-04-21
Accepted
2023-04-21 08:10:21
Documents
14
Period of Report
2023-04-19
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc20051717_8k.htm   iXBRL 8-K 37690
2 EXHIBIT 99.1 brhc20051717_ex99-1.htm EX-99.1 13348
6 image00001.jpg GRAPHIC 5650
  Complete submission text file 0001140361-23-019505.txt   203591

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ocup-20230419.xsd EX-101.SCH 3865
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ocup-20230419_lab.xml EX-101.LAB 22546
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ocup-20230419_pre.xml EX-101.PRE 16044
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc20051717_8k_htm.xml XML 4242
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Ocuphire Pharma, Inc. (Filer) CIK: 0001228627 (see all company filings)

IRS No.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 23834616
SIC: 2834 Pharmaceutical Preparations